Announcements Trials

Browse Landscape

Phase

Status

Recruiting 2 Completed 2 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nalbuphine Allergy 1

Interventions

Cisplatin 352 Oxaliplatin 262 Capecitabine 258 Radiotherapy 240 Gemcitabine 223 Docetaxel 223 Carboplatin 223 Cyclophosphamide 219 Drug Therapy 218 Paclitaxel 205 apatinib 201 Bevacizumab 195 camrelizumab 190 Fluorouracil 187 sintilimab 133 Blood Specimen Collection 125 Irinotecan 124 Dexamethasone 123 Etoposide 119 Radiosurgery 118 toripalimab 117 Surgical Procedures, Operative 115 pembrolizumab 110 Pemetrexed 108 anlotinib 105 S 1 (combination) 105 Surveys and Questionnaires 101 Leucovorin 101 Nivolumab 98 tislelizumab 96

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × OTHER × Nalbuphine × Clear all

NCT05073744 2022-12-29

Nalbuphine Versus Morphine for Perioperative Tumor Ablation

Zhongda Hospital

Phase 4 Unknown

Nalbuphine Allergy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡